nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—Loss of libido—Octreotide—thymus cancer	0.0677	0.0766	CcSEcCtD
Valsartan—Viral infection—Octreotide—thymus cancer	0.0346	0.0391	CcSEcCtD
Valsartan—Drug interaction—Octreotide—thymus cancer	0.0337	0.0381	CcSEcCtD
Valsartan—Hyperkalaemia—Octreotide—thymus cancer	0.0307	0.0347	CcSEcCtD
Valsartan—Abdominal pain upper—Octreotide—thymus cancer	0.0207	0.0234	CcSEcCtD
Valsartan—Cramp muscle—Octreotide—thymus cancer	0.0204	0.0231	CcSEcCtD
Valsartan—Muscular weakness—Octreotide—thymus cancer	0.02	0.0226	CcSEcCtD
Valsartan—Bronchitis—Octreotide—thymus cancer	0.0189	0.0213	CcSEcCtD
Valsartan—Upper respiratory tract infection—Octreotide—thymus cancer	0.0182	0.0206	CcSEcCtD
Valsartan—Epistaxis—Octreotide—thymus cancer	0.0165	0.0186	CcSEcCtD
Valsartan—Sinusitis—Octreotide—thymus cancer	0.0164	0.0186	CcSEcCtD
Valsartan—Rhinitis—Octreotide—thymus cancer	0.0157	0.0178	CcSEcCtD
Valsartan—Hepatitis—Octreotide—thymus cancer	0.0157	0.0177	CcSEcCtD
Valsartan—Pharyngitis—Octreotide—thymus cancer	0.0156	0.0176	CcSEcCtD
Valsartan—Cardiac disorder—Octreotide—thymus cancer	0.0146	0.0165	CcSEcCtD
Valsartan—Immune system disorder—Octreotide—thymus cancer	0.0142	0.016	CcSEcCtD
Valsartan—AGTR1—neck—thymus cancer	0.0141	0.122	CbGeAlD
Valsartan—Alopecia—Octreotide—thymus cancer	0.0139	0.0157	CcSEcCtD
Valsartan—Mental disorder—Octreotide—thymus cancer	0.0138	0.0156	CcSEcCtD
Valsartan—Malnutrition—Octreotide—thymus cancer	0.0137	0.0155	CcSEcCtD
Valsartan—Flatulence—Octreotide—thymus cancer	0.0135	0.0152	CcSEcCtD
Valsartan—Back pain—Octreotide—thymus cancer	0.0132	0.0149	CcSEcCtD
Valsartan—Muscle spasms—Octreotide—thymus cancer	0.0131	0.0149	CcSEcCtD
Valsartan—Vision blurred—Octreotide—thymus cancer	0.0129	0.0146	CcSEcCtD
Valsartan—SLCO1B3—pituitary gland—thymus cancer	0.0129	0.111	CbGeAlD
Valsartan—Vertigo—Octreotide—thymus cancer	0.0123	0.0139	CcSEcCtD
Valsartan—Syncope—Octreotide—thymus cancer	0.0123	0.0139	CcSEcCtD
Valsartan—Palpitations—Octreotide—thymus cancer	0.0121	0.0137	CcSEcCtD
Valsartan—Loss of consciousness—Octreotide—thymus cancer	0.012	0.0136	CcSEcCtD
Valsartan—Cough—Octreotide—thymus cancer	0.0119	0.0135	CcSEcCtD
Valsartan—Myalgia—Octreotide—thymus cancer	0.0116	0.0132	CcSEcCtD
Valsartan—Arthralgia—Octreotide—thymus cancer	0.0116	0.0132	CcSEcCtD
Valsartan—Chest pain—Octreotide—thymus cancer	0.0116	0.0132	CcSEcCtD
Valsartan—Anxiety—Octreotide—thymus cancer	0.0116	0.0131	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.0116	0.0131	CcSEcCtD
Valsartan—Dry mouth—Octreotide—thymus cancer	0.0114	0.0129	CcSEcCtD
Valsartan—Anaphylactic shock—Octreotide—thymus cancer	0.0112	0.0126	CcSEcCtD
Valsartan—Oedema—Octreotide—thymus cancer	0.0112	0.0126	CcSEcCtD
Valsartan—Infection—Octreotide—thymus cancer	0.0111	0.0125	CcSEcCtD
Valsartan—Shock—Octreotide—thymus cancer	0.011	0.0124	CcSEcCtD
Valsartan—Nervous system disorder—Octreotide—thymus cancer	0.0109	0.0124	CcSEcCtD
Valsartan—Thrombocytopenia—Octreotide—thymus cancer	0.0109	0.0123	CcSEcCtD
Valsartan—Skin disorder—Octreotide—thymus cancer	0.0108	0.0122	CcSEcCtD
Valsartan—Anorexia—Octreotide—thymus cancer	0.0106	0.012	CcSEcCtD
Valsartan—AGTR1—hematopoietic system—thymus cancer	0.0105	0.0909	CbGeAlD
Valsartan—Musculoskeletal discomfort—Octreotide—thymus cancer	0.0102	0.0115	CcSEcCtD
Valsartan—Insomnia—Octreotide—thymus cancer	0.0101	0.0114	CcSEcCtD
Valsartan—SLCO1B3—lung—thymus cancer	0.0101	0.087	CbGeAlD
Valsartan—SLCO1B1—hematopoietic system—thymus cancer	0.01	0.0867	CbGeAlD
Valsartan—Paraesthesia—Octreotide—thymus cancer	0.01	0.0113	CcSEcCtD
Valsartan—Dyspnoea—Octreotide—thymus cancer	0.00994	0.0112	CcSEcCtD
Valsartan—Somnolence—Octreotide—thymus cancer	0.00991	0.0112	CcSEcCtD
Valsartan—Dyspepsia—Octreotide—thymus cancer	0.00982	0.0111	CcSEcCtD
Valsartan—Decreased appetite—Octreotide—thymus cancer	0.00969	0.011	CcSEcCtD
Valsartan—Gastrointestinal disorder—Octreotide—thymus cancer	0.00963	0.0109	CcSEcCtD
Valsartan—Fatigue—Octreotide—thymus cancer	0.00961	0.0109	CcSEcCtD
Valsartan—AGTR1—epithelium—thymus cancer	0.00961	0.0831	CbGeAlD
Valsartan—Constipation—Octreotide—thymus cancer	0.00954	0.0108	CcSEcCtD
Valsartan—Gastrointestinal pain—Octreotide—thymus cancer	0.00912	0.0103	CcSEcCtD
Valsartan—Urticaria—Octreotide—thymus cancer	0.00886	0.01	CcSEcCtD
Valsartan—Abdominal pain—Octreotide—thymus cancer	0.00882	0.00997	CcSEcCtD
Valsartan—Hypersensitivity—Octreotide—thymus cancer	0.00822	0.00929	CcSEcCtD
Valsartan—Asthenia—Octreotide—thymus cancer	0.008	0.00905	CcSEcCtD
Valsartan—AGTR1—cardiac atrium—thymus cancer	0.00799	0.069	CbGeAlD
Valsartan—Pruritus—Octreotide—thymus cancer	0.00789	0.00892	CcSEcCtD
Valsartan—AGTR1—pituitary gland—thymus cancer	0.0078	0.0674	CbGeAlD
Valsartan—Diarrhoea—Octreotide—thymus cancer	0.00763	0.00863	CcSEcCtD
Valsartan—AGTR1—lymphoid tissue—thymus cancer	0.0074	0.064	CbGeAlD
Valsartan—Dizziness—Octreotide—thymus cancer	0.00737	0.00834	CcSEcCtD
Valsartan—Vomiting—Octreotide—thymus cancer	0.00709	0.00802	CcSEcCtD
Valsartan—Rash—Octreotide—thymus cancer	0.00703	0.00795	CcSEcCtD
Valsartan—Dermatitis—Octreotide—thymus cancer	0.00702	0.00794	CcSEcCtD
Valsartan—Headache—Octreotide—thymus cancer	0.00699	0.0079	CcSEcCtD
Valsartan—AGTR1—thyroid gland—thymus cancer	0.00672	0.0581	CbGeAlD
Valsartan—Nausea—Octreotide—thymus cancer	0.00662	0.00749	CcSEcCtD
Valsartan—AGTR1—lung—thymus cancer	0.00611	0.0528	CbGeAlD
Valsartan—CYP2C9—hematopoietic system—thymus cancer	0.00506	0.0438	CbGeAlD
Valsartan—AGTR1—lymph node—thymus cancer	0.00418	0.0361	CbGeAlD
Valsartan—ALB—lymph node—thymus cancer	0.00322	0.0279	CbGeAlD
